Roth Capital Partners is set to host its 5th Annual Healthcare Opportunities Conference on Sept. 29, 2026, at the Metropolitan Club in New York City. The invitation-only event will bring together C-suite executives from more than 30 public healthcare companies and leading institutional investors for a day of focused engagement and discussion.
The conference will feature one-on-one and small-group meetings with companies representing biotechnology, life science tools and diagnostics, and medical technology. In addition to these meetings, the event will include discussions on key industry topics such as neuroscience, drug pricing and coverage, regulatory uncertainty, capital constraints in biotechnology, and minimal residual disease (MRD) monitoring in solid tumors.
The event will be hosted by ROTH senior healthcare research analysts Jonathan Aschoff, Ph.D., Max Masucci, Boobalan Pachaiyappan, Ph.D., and Adam Walsh, MD. Their expertise will guide conversations that are critical to understanding the current healthcare investment landscape.
Since 2010, ROTH has been involved in more than 600 transactions for healthcare clients representing more than $25 billion in total transaction value. This track record underscores the firm's deep relationships and industry knowledge, which are central to the conference's value proposition. For those interested in attending or learning more about the full calendar of events, visit https://ibn.fm/vDTjP.
ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Its full-service platform spans capital raising, high-impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately held, employee-owned firm with offices across the U.S. For more information, visit www.roth.com.
The conference is being publicized through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. InvestorWire offers wire-grade press release syndication and editorial syndication to 5,000+ outlets, along with press release enhancement and social media distribution to millions of followers.
For healthcare investors and industry professionals, this conference represents a timely opportunity to gain insights into pressing issues such as drug pricing, regulatory hurdles, and capital constraints that are shaping the biotechnology and medical technology sectors. The focus on MRD monitoring in solid tumors highlights an area of growing importance in precision oncology, where improved monitoring can influence treatment decisions and outcomes. As healthcare companies navigate a complex funding environment, events like this can foster connections that drive innovation and investment. The discussions may also signal emerging trends in neuroscience and diagnostics, areas that are attracting significant attention and capital. Overall, the conference serves as a barometer for the health of the healthcare investment ecosystem and could impact how companies strategize their research, development, and commercialization efforts.
